CRISPR Therapeutics $2.4 Billion Cash: Why the Stock Slump Persists
CRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
This guide shows how indices are grouped by country and region, enabling easier cross-market comparisons and analysis.
28,656 articlesCRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
Venture capital giants surge into crypto and AI with a historic fund, stirring a volatile mix of policy headlines and...
What if one cryptocurrency could outgrow Bitcoin and Ethereum combined? This article dives into the drivers, risks, a...
Alysa Liu’s historic win isn’t just a sports milestone—it's a finance case study for athletes. This piece breaks down...
DTCC’s real-world asset push is reshaping the institutional crypto stack. On one side lies Canton Network’s private-r...
Two new AI music models from ElevenLabs and Stability AI promise bigger creative horizons, with open weights and long...
A new era of autonomous AI agents could turbocharge voice tech leaders. Learn how agentic will supercharge soundhound...
Trad.Fi and W3 unveil a four-year plan to put a $650 million private-credit pipeline on blockchain rails, aiming to c...
Chasing a meme coin with best odds of lasting requires more than hype. This guide breaks down real-world factors, sim...
World Liberty Financial’s WLFI rebound opens an exit window for dormant holders, even as AI Financial cautions that t...
As the 2026 World Cup draws global attention, a bold CEO taps the frenzy to build lasting personal-finance products f...
When a Federal Reserve chair signals a preference for policy stability over boom-and-bust cycles, it can upend how in...